Patients Switching to Oral Wegovy Continue Weight Loss in Real-World Study
A real-world study presented by Novo Nordisk shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to the new oral version of Wegovy continued losing weight over three months. On average, participants lost about 4% of their body weight—roughly 8.8 pounds—with an initial starting weight around 221 pounds. The study suggests that patients may prefer and benefit from switching to a pill format for convenience without compromising results. The data comes from Ro's telehealth platform involving 194 participants, with half initially on Wegovy injections and the other half using Zepbound. About two in five achieved at least 5% weight loss after three months of taking the oral medication. Additionally, more than a fifth saw their BMI drop below 30, moving them from obesity to overweight status. Novo Nordisk's chief scientific officer noted that patients reported improvements such as better-fitting clothes and healthier eating habits. While real-world data has limitations—such as self-reporting bias—the results highlight growing patient preference for oral treatments over injections.
Topics: obesity treatment semaglutide tablets Wegovy weight loss data